You are here: Industry Insights > SOTIO

News List

SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors B3Cnewswire
December 09, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD...
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline B3Cnewswire
December 03, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101...
SOTIO, LegoChem Biosciences Enter ADC License Agreement ContractPharma
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company, entered an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc., a biotechnology company...
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences B3Cnewswire
November 17, 2021
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc...
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting b3cnewswire
June 07, 2021
SOTIO today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.
SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics b3cnewswire
September 01, 2020
SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has acquired the rights to Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment
Sotio Acquires Rights to BOXR Cell Therapy Platform contractpharma
September 01, 2020
Sotio, a clinical stage immuno-oncology company owned by PPF Group, has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors.
SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors b3cnewswire
July 14, 2020
SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic soli
SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II B3C newswire
July 01, 2020
SOTIO and Cytune Pharma from the PPF Group, today presented new preclinical data highlighting the therapeutic potential of SO-C101, an IL-15 superagonist, as a monotherapy and in combination with PD-1 inhibitors in multiple tumor models.
SOTIO Appoints Richard Sachse as Chief Medical Officer b3cnewswire
July 01, 2020
SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective July 1, 2020. Dr. Sachse brings more than 25 years of experience in the biopharma indust

Previous page 1 2 Next page